This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
Tip of the Month
Tip of the month - The advantage of adding a 3rd or 4th drug may be negligible
The advantage of adding a 3rd or 4th drug may be negligible

Publishing date: April 2011

Tip Editors: Ann Hoste, John Salmon and John Thygesen
Tip reviewer: Roger Hitchings


The Science behind the Tip

With the arrival of combination products, our threshold for prescribing multiple glaucoma medications has significantly decreased. These products enhance compliance by simplifying therapeutic regimens. They reduce exposure to the preservative benzalkonium chloride. And if fewer drops are used, then washout effects are less likely. Further, and for reasons still poorly understood, some drugs tend to be better tolerated locally when given in combination with timolol. This is the case for brimonidine in Combigan (1) and bimatoprost in Ganfort (2).  It is the impression of clinicians that this also holds true for dorzolamide in Cosopt, although there are no studies corroborating (or contradicting) this.

All these convenient aspects of combination products should not, however, make us forget to strive to limit drug use to the minimum necessary. Polypharmacy does carry a higher risk of side-effects, be it allergies, ocular surface disease or drug-specific adverse events. In a retrospective study, adding a 3rd or 4th drug to an existing regimen produced a clinically significant reduction in intraocular pressure in about half the patients (3). However, the cumulative probability of efficacy and safety success over the long term (based on the need for surgical intervention and/or the occurrence of intolerable side effects) was rather poor. It was 27% at 6 months and 14% at 1 year for adding a 3rd drug, and 31% and 14%, respectively, for adding a 4th.

In any case it is not useful to associate 2 combination products because they all contain timolol 0.5%.


Contributor: Ann Hoste, Antwerp




References

1. Motolko MA.  Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin. 2008;24:2663-7.

2. Paranhos A, Mendonça M, Silva MJ, et al. Hyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy. J Ocul Pharmacol Ther. 2010;26:611-5.

3. Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13:130-6.




back to top